Rituximab not beneficial long-term in Sjorgen’s Syndrome
Image: PD 1. The results of this study suggest that rituximab (Rituxin) treatment is not associated with a significant improvement ...
Image: PD 1. The results of this study suggest that rituximab (Rituxin) treatment is not associated with a significant improvement ...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
Image: PD AML 1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell ...
Image: PD/Rituximab (Rituxan, MabThera) 1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar ...
Image: PD 1. Rituximab is non-inferior to cyclophosphamide in inducing remission of severe ANCA-associated vasculitis. 2. There were no significant ...
May 20 - 27, 2013 In this section, we will highlight the some of the high-impact studies, updates, and analyses ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.